Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Anoro Ellipta (umeclidinium/vilanterol) and Symbicort (budesonide/formoterol) are both inhalers used to manage chronic obstructive pulmonary disease (COPD), but they have some key differences. Anoro Ellipta combines a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA), while Symbicort combines a corticosteroid and a LABA. Anoro Ellipta is taken once daily, whereas Symbicort is taken twice daily. Symbicort is also approved for treating asthma, unlike Anoro Ellipta. Anoro Ellipta does not have a generic version, making it potentially more expensive, while Symbicort is available in generic forms. Additionally, Anoro Ellipta does not require mouth rinsing after use, but Symbicort does to prevent thrush. Both medications are not suitable for sudden breathing problems and should be used as long-term maintenance treatments.
Symbicort (budesonide / formoterol) is a combination inhaler containing a steroid (budesonide) and a long-acting beta-agonist (formoterol). Both medications work together to treat asthma and chronic obstructive pulmonary disease (COPD). The typical dose for Symbicort (budesonide / formoterol) is 2 inhalations by mouth twice a day, about 12 hours apart. Common side effects include symptoms of common cold, such as stuffy nose and cough. It's available in two different strengths, both with generic versions.